Use of Lidocaine in Rapid Sequence Induction

Not Applicable

Completed

• Conditions: Hemodynamic Response
• Interventions: Drug: Placebo; Drug: Lidocaine

• Registration Number: NCT01238718
• Lead Sponsor: University of Athens

Brief Summary

Lidocaine has been shown to blunt the cardiovascular response to endotracheal intubation. The incidence of hypertension, tachycardia and dysrhythmias due to laryngoscopy may be increased in patients that receive rapid sequence induction and intubation, where opioids are spared and intravenous anesthetic agents are not titrated step by step. Our hypothesis was that lidocaine when administered intravenously in patients who undergo rapid sequence induction may not only blunt the hemodynamic response to intubation, but may also increase the anesthetic depth (as assessed by BIS), thus further reducing the possibility of hypertension, arrhythmias and also awareness.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-10
• Status Verified: 2010-11
• Study First Submitted: 2010-11-08
• Study First Submitted QC: 2010-11-10
• Study First Posted: 2010-11-11
• Primary Completion: 2011-07
• Study Completion: 2011-07
• Last Update Submitted: 2011-08-23
• Last Update Posted: 2011-08-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

• reason for rapid sequence induction (emergency, reflux),
• ASA I-II,
• no antihypertensive drugs,
• no antiarrhythmic drugs

Exclusion Criteria :

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
normal saline	Placebo	-
lidocaine	Lidocaine	-

Primary Outcome Measures

Name	Time	Method
BIS changes after lidocaine administration in rapid sequence induction	change from baseline in BIS values during 10 minutes

Secondary Outcome Measures

Name	Time	Method
change in blood pressure	change from baseline in blood pressure during 10 minutes
change in Heart rate	change from baseline in heart rate durng 10 minutes

Trial Locations

Locations (1)

Aretaieio Hospital, University of Athens; 🇬🇷 Athens, Attiki, Greece